The World Health Organization’s (WHO) Strategic Advisory Group on Immunization (SAGE) made several recommendations on the safety and effectiveness of the Covid-19 vaccine Pfizer.
According to SAGE’s updated guidelines at the end of June 2021, the Pfizer/BioNTech vaccine is considered safe and effective. Specifically, this vaccine is 95% effective in preventing symptomatic Covid-19 infection.
Who should be vaccinated first?
In the context of limited vaccine supply, SAGE believes that priority should be given to vaccination of healthcare workers at high risk of exposure and people 65 years of age and older.
Who else can get the vaccine?
This vaccine has been shown to be safe and effective in people with multiple underlying medical conditions, at high risk for serious illness, including: hypertension, diabetes, asthma, lung, liver or kidney disease, as well as chronic infectious diseases. stabilized and under control.
SAGE believes that more studies on the effects in immunocompromised individuals are needed. The interim recommendation is that immunocompromised individuals – those in the recommended vaccination category – may be vaccinated after information and counseling are provided.
People who are living with HIV are at higher risk of severe Covid-19 infection. Currently, there are few safety data in people living with HIV in clinical vaccine trials. Therefore, people living with HIV should be counseled to weigh the benefits and risks before vaccination.
It is possible to vaccinate people who have had Covid-19. However, due to the limited supply of vaccine, these people can delay vaccination about 6 months from the time of infection.
Vaccine efficacy in lactating women is estimated to be similar to that of other adults. And they don’t need to stop breastfeeding during the vaccination.
Should pregnant women be vaccinated?
SAGE recommends the use of the Covid-19 vaccine in pregnant women when the benefits of vaccinating pregnant women outweigh the potential risks. To help pregnant women make this assessment, information should be provided on the risk of Covid-19 during pregnancy and the benefits of vaccination in the local epidemiological context, and Current limitations on safety data in pregnant women.
SAGE does not recommend pre-vaccination diagnostic pregnancy testing, nor does it recommend delaying pregnancy or termination of pregnancy for reasons of Covid-19 vaccination.
Who should not get this vaccine?
Individuals with a history of severe allergy to any component of the vaccine should not receive this vaccine.
There are currently no data on efficacy or safety in children under 12 years of age. Until these data are available, children under 12 years of age should not be routinely vaccinated with this vaccine.
Can this vaccine be used in adolescents?
The phase three trial in children 12-15 years old showed that the vaccine was highly effective and safe in this age group, thus expanding the previous age designation from 16 years and older to 12 years and older.
Evidence shows that adolescents, especially the older group, are just as likely to spread Covid-19 as adults.
Children aged 12 to 15 years have comorbidities that put them at higher risk of severe Covid-19 so this group may need to be vaccinated.
The protective effect begins 12 days after the first dose, but full protection requires two doses as recommended by WHO, with an interval of 21-28 days. More research is needed to better understand the potential long-term protection after a single dose. Currently, it is recommended to use the same product for both doses. Countries with high rates of Covid-19 and severe vaccine supply shortages may consider delaying doses by 2 to 12 weeks to achieve higher first-line coverage in high-priority groups.
Is this vaccine safe?
WHO granted emergency use authorization for Pfizer/BioNTech’s Covid-19 vaccine on December 31, 2020. WHO has thoroughly evaluated the quality, safety and efficacy of this vaccine and recommends it for use in people over 16 years of age.
The Global Advisory Committee on Vaccine Safety is a group of experts that provides WHO independent and authoritative guidance on the topic of the safe use of vaccines, and has received and evaluated reports of suspected safety incidents. capable of international influence.
Does this vaccine work with new variants?
SAGE has reviewed all available data on the efficacy of this vaccine in trials to assess its efficacy against new variants. These trials show that the vaccine is effective against the new variants.
Currently, SAGE recommends using the Pfizer/BioNTech vaccine under the WHO Priority Roadmap, even if a new variant of the virus appears in the country. When countries assess risks and benefits, local epidemiological considerations should be taken into account.
The initial findings highlight the urgent need for close coordination in monitoring and evaluation of variants and their potential impact on vaccine efficacy. As new data becomes available, WHO will update its recommendations.
Does this vaccine prevent infection and transmission?
There are not many data available on the impact of the Pfizer/BioNTech vaccine on virus transmission or release. At the same time, we still have to maintain effective public health measures: wearing masks, keeping a safe distance, washing hands, respiratory hygiene and rules of covering coughs, avoiding large gatherings, and ensure good ventilation.
Pfizer vaccine in Vietnam
On June 12, the Ministry of Health conditionally approved the Covid-19 vaccine Pfizer/BioNTech, serving the urgent needs of epidemic prevention and control. This vaccine is prepared in the form of a concentrated suspension for injection, each dose of 0.3 ml contains 30 mcg of Covid-19 mRNA vaccine (encapsulated in lipid nanoparticles), manufactured in Belgium and Germany. This is the fourth Covid-19 vaccine to be urgently approved by Vietnam, after AstraZeneca (UK), Sputnik V (Russia) and Sinopharm (China).
On July 7, more than 97,000 doses of pfizer vaccine arrived at Noi Bai airport. This is the first batch in Pfizer/BioNtech’s commitment to supply 31 million doses of vaccine to Vietnam in 2021. It is expected that in July another batch of Pfizer’s Covid-19 vaccine will be added to Vietnam.
Pfizer vaccine is prepared by mRNA technology, bringing genetic information of nCoV into the body. Vaccines provide information about the “template” of the virus that does not cause disease. Templates allow the immune system to get used to pathogens and destroy them later.
Currently, this vaccine is used in 103 countries.